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ABSTRACT

DECIDE study (ClinicalTrials.gov identifier,
NCT01064401).

Introduction: Cutaneous adverse events (AEs)
have been observed in clinical studies of

Methods: DECIDE
was
a
randomized,
double-blind, active-controlled phase 3 study

daclizumab high-yield process (HYP) in
relapsing-remitting multiple sclerosis (RRMS).

of daclizumab HYP 150 mg subcutaneous every
4 weeks versus interferon (IFN) beta-1a 30 mcg

Here, we report cutaneous AEs observed in the

intramuscular (IM) once weekly in RRMS.

randomized, double-blind, active-comparator

Treatment-emergent AEs were classified and
recorded by investigators. Investigators also
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assessed the severity of each AE, and whether
it met the criteria for a serious AE. Cutaneous
AEs were defined as AEs coded to the Medical
Dictionary for Regulatory Activities System
Organ Class of skin and subcutaneous tissue
disorders.

The

incidence,

severity,

onset,

A. Friedman
Department of Dermatology, George Washington
University School of Medicine and Health Sciences,
22nd & I Street NW, Washington, DC 20037, USA
X. You  N. Lucas  M. Sweetser 
W. Castro-Borrero  P. McCroskery  J. Elkins
Biogen, 225 Binney Street, Cambridge, MA 02142,
USA
Present Address:
X. You
Vertex Pharmaceuticals, 50 Northern Avenue,
Boston, MA 02210, USA

Adv Ther

resolution, and management of AEs were

INTRODUCTION

analyzed by treatment group.
Results: Cutaneous AEs were reported in 37%

Daclizumab high-yield process (HYP) is a

of daclizumab HYP-treated patients and 19% of
IFN beta-1a-treated patients. The most common

humanized monoclonal antibody targeted
against CD25, the interleukin 2 receptor alpha

investigator-reported

with

subunit [1]. Interleukin 2 is a cytokine produced

daclizumab HYP were rash (7%) and eczema
(4%). Most patients with cutaneous AEs

by activated T cells that regulates both immune
responses and the maintenance of self-tolerance

remained on treatment (daclizumab HYP,
81%; IM IFN beta-1a, 90%) and had events

[2]. Blockade of CD25 showed promising results in
T cell-mediated autoimmune disorders, including

that were mild or moderate (94% and 98%) and

in pilot studies in multiple sclerosis (MS) [3–5].

subsequently resolved (78% and 82%). Most
patients with cutaneous AEs did not require

Subsequently, the efficacy and safety of
daclizumab HYP have been evaluated in clinical

treatment with corticosteroids or were treated
with topical corticosteroids (daclizumab HYP,

studies in relapsing-remitting MS (RRMS) [6, 7].
In the pivotal 1-year SELECT study

73%; IM IFN beta-1a, 81%). Serious cutaneous

(ClinicalTrials.gov identifier, NCT00390221),

AEs were reported in 14 (2%) daclizumab HYP
patients and one (\1%) IM IFN beta-1a patient.

daclizumab HYP 150 mg subcutaneous (SC)
every 4 weeks significantly reduced relapses,

Conclusion: There was an increased risk of
cutaneous AEs with daclizumab HYP. While

12-week confirmed disability progression, and
brain lesions on magnetic resonance imaging

physicians should be aware of the potential for
serious cutaneous AEs, the typical cutaneous

(MRI) compared with placebo [6]. Daclizumab

cutaneous

AEs

severity,

HYP also showed superior efficacy to interferon
(IFN) beta-1a 30 mcg intramuscular (IM) once

manageable, and resolved over time.
Funding: Biogen and AbbVie Biotherapeutics

weekly with respect to annualized relapse rate,
MRI lesion activity, and 24-week confirmed

Inc.
Trial registration: ClinicalTrials.gov identifier,

disability

AEs

were

mild-to-moderate

in

progression

over

2–3 years

of

NCT01064401.

treatment in the active-comparator phase 3
DECIDE study (ClinicalTrials.gov identifier,

Keywords: Cutaneous

Daclizumab

NCT01064401) [7]. Based on the safety profile
of daclizumab HYP in SELECT [6], one of the

high-yield process; Dermatology; Interferon

adverse events (AEs) of interest in DECIDE was

beta; Neurology; Relapsing-remitting multiple
sclerosis; Safety

cutaneous AEs. The objective of this report is to
provide a description of the frequency and

events;

character of cutaneous AEs in DECIDE.

METHODS
S. J. Greenberg
AbbVie, 1 North Waukegan Road, North Chicago,
IL 60064, USA

Standard Protocol Approvals,

Present Address:
M. Sweetser
Alnylam Pharmaceuticals, Inc., 300 Third Street,
Cambridge, MA 02142, USA

The DECIDE study protocol was approved by

Registrations, and Patient Consents

central and local ethics committees, and the
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study was conducted in accordance with the

whether an AE met the criteria for a serious AE

International Conference on Harmonisation

based on guidance in the protocol (please see

Guideline for Good Clinical Practice and the
Declaration of Helsinki of 1964, as revised in

Table S1 in the supplementary material for
details). A serious AE was an AE that resulted in

2008
[8].
DECIDE
was
registered
at
ClinicalTrials.gov (NCT01064401). All patients

hospitalization/prolongation of hospitalization,
disability/incapacity, a congenital anomaly/birth

provided written informed consent before

defect, or death, or in the opinion of the

participating
photographs

investigator was life-threatening. Medical
history of rash, dermatitis, eczema, or psoriasis

in the study and before
were used for educational

was derived from a search of patients’ medical
history obtained at enrollment.

purposes.
Trial Design and Patients

An

independent

central

dermatologist

randomized,

blinded to study treatment reviewed and
provided assessments of clinically significant

double-blind, double-dummy, active-controlled,
phase 3 study to evaluate the efficacy and safety of

events and the overall pattern of cutaneous AEs
to the study’s data safety monitoring board. In

daclizumab HYP versus IM IFN beta-1a [7]. The
study design and patient eligibility criteria have

addition, guidelines for the management of

DECIDE

was

a

multicenter,

been previously reported [7]. Briefly, patients with

patients with cutaneous AEs were developed
and provided to the study investigators,

a confirmed diagnosis of RRMS (2005 McDonald
criteria 1–4) [9] were randomized 1:1 to receive

although implementation of these guidelines
was not mandated by the protocol (see

daclizumab HYP 150 mg SC every 4 weeks or IFN
beta-1a 30 mcg IM once weekly for a minimum of

Appendix S1).
To provide a visual frame of reference,

96 weeks up to a maximum of 144 weeks. The
study ended when the last enrolled patient

photographs of mild, moderate, and severe

completed 96 weeks of treatment.

events in daclizumab HYP-treated patients
were
selected
for
inclusion
in
the

Safety Assessments

manuscript from a limited subset for which
patients had provided written consent for
educational use.

Treatment-emergent AEs and serious AEs, defined
as events that started after the first dose of study
drug and up to 180 days after the last dose, were

Data Analyses

monitored,

by

Cutaneous AEs were defined as all events coded

investigators throughout the study. Serious AEs
were followed until the event resolved, stabilized,

to the Medical Dictionary for Regulatory
Activities (MedDRA; version 16.1) System

or returned to baseline, even in patients who had
completed
or
discontinued
the
study.

Organ Class of skin and SC tissue disorders.

classified,

and

recorded

(mild,

This System Organ Class does not include the
Preferred Terms directly related to injection site

moderate, severe), whether AEs and serious AEs
were or were not related to study treatment, and

reactions. The incidence of AEs was analyzed
based on treatment group.

Investigators

assessed

AE

severity
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RESULTS
Patients and Study Drug Exposure
DECIDE enrolled 1841 patients with RRMS; 919
were randomized and treated with daclizumab
HYP and 922 were treated with IM IFN beta-1a.
At baseline, patient demographic and clinical
characteristics were similar between treatment
groups [7]. Briefly, 68% of patients were female,
90% were white, and 41% had received prior
treatment with disease-modifying therapies in
each treatment group. In the daclizumab HYP
and IM IFN beta-1a groups, the mean (standard
deviation) age was 36.4 (9.4) and 36.2 (9.3)
years, respectively. At baseline, 16% of patients
in each treatment group had a medical history
of a dermatological condition.
The mean (median) time on treatment was
102.0 (108.7; range 0.1–145.3) weeks and 100.5
(111.4;

range

0.1–146.1)

weeks

in

the

daclizumab HYP and IM IFN beta-1a groups,
representing 1797.2 and 1776.6 patient-years of
treatment exposure, respectively.
Cutaneous AE Onset and Severity
Treatment-emergent cutaneous AEs were
reported at generally stable rates in both
groups when analyzed by 12-week intervals
over 96 weeks of treatment, although the rates
were consistently higher with daclizumab HYP

Fig. 1 Incidence of all cutaneous AEs (a) and moderate or
severe cutaneous AEs (b) by 12-week intervals during the
treatment period. The numbers of patients represents the
safety population evaluated during those intervals. AE
adverse event, HYP high-yield process, IFN interferon, IM
intramuscular
after the last dose (daclizumab HYP, \1%; IM
IFN beta-1a, \1%). Cutaneous AEs were more
frequently assessed by the investigator as being
related to study treatment in daclizumab

than with IM IFN beta-1a (Fig. 1a). The
cumulative incidence of cutaneous AEs was

HYP-treated patients (15%) than in IM IFN
beta-1a-treated patients (7%).

37% in the daclizumab HYP group compared

The most common cutaneous AEs (C2% of
patients in either treatment group) are listed in

with 19% in the IM IFN beta-1a group over the
course of the study. During the 6-month period
after the last dose of study treatment, the
incidence of cutaneous AEs remained higher
in the daclizumab HYP group (21%) compared
with the IM IFN beta-1a group (5%), but was
similar between the groups beyond 6 months

Table 1. Dermatitis, eczema, and rashes were
among the most common investigator-reported
Preferred Terms for cutaneous AEs (Table 1).
There was a 1.5- to 2.0-fold higher incidence of
cutaneous AEs in patients with a medical
history of rash, dermatitis, eczema, or psoriasis

Adv Ther

Table 1 Incidence of cutaneous AEs that occurred in
C2% of either treatment group
MedDRA High Level
Term, n (%)
Preferred Term

IM IFN
beta-1a
(n 5 922)

Daclizumab
HYP
(n 5 919)

Dermatitis and
eczema

51 (6)

133 (14)

13 (1)

40 (4)

Eczema
Seborrhoeic
dermatitis

4 (\1)

Dermatitis

8 (\1)

20 (2)

Allergic dermatitis

5 (\1)

19 (2)

Contact dermatitis
Atopic dermatitis
Rashes, eruptions,
and exanthems
Rash
Maculopapular rash
Dermal and
epidermal
conditions
Dry skin
Acnes
Acne

14 (2)
3 (\1)

28 (3)

16 (2)

MedDRA High Level
Term, n (%)
Preferred Term

IM IFN
beta-1a
(n 5 922)

Apocrine and eccrine
gland disorders

12 (1)

Daclizumab
HYP
(n 5 919)
17 (2)

Alopecias

9 (\1)

16 (2)

Alopecia

9 (\1)

16 (2)

Patients were only counted once with each High Level
Term/Preferred Term. Cutaneous AEs listed in
descending order in the daclizumab HYP group
AE adverse event, HYP high-yield process, IFN interferon,
IM intramuscular, MedDRA Medical Dictionary for
Regulatory Activities

14 (2)

33 (4)

89 (10)

26 (3)

64 (7)

than in those with no medical history of these
4 (\1)
12 (1)

17 (2)

conditions in both the daclizumab HYP
(history: 56%, 85/152 vs no history: 34%,

38 (4)

259/767) and IM IFN beta-1a (history: 35%,
58/164 vs no history: 16%, 118/758) groups.
Cutaneous AEs represented 30% (43/142) and

6 (\1)
11 (1)
9 (\1)

22 (2)
32 (3)
29 (3)

Erythemas

14 (2)

32 (3)

Erythema

14 (2)

28 (3)

16 (2)

32 (3)

Pruritus

15 (2)

25 (3)

Urticarias

17 (2)

24 (3)

Urticaria

15 (2)

19 (2)

Pruritus

Table 1 continued

of AE-related study withdrawals in the daclizumab
HYP and IM IFN beta-1a groups. Cutaneous AEs
led to treatment discontinuation in a higher
percentage of daclizumab HYP-(5%) versus IM
IFN beta-1a-treated (\1%) patients (Table 2). Most
patients with cutaneous AEs had no action taken
with their study drug as a result of the event
(daclizumab HYP, 80.5%; IM IFN beta-1a, 89.8%;
Table 2).
The majority of patients with cutaneous AEs

Exfoliative
conditions

4 (\1)

Papulosquamous
conditions

5 (\1)

19 (2)

severity (daclizumab HYP: 94%, 323/344; IM
IFN beta-1a: 98%, 173/176). The most common

Psoriatic conditions

3 (\1)

18 (2)

2 (\1)

14 (2)

mild and moderate cutaneous AEs (C2% of
patients in either treatment group) are listed in

Psoriasis

20 (2)

6% (7/112) of all AE-related treatment
discontinuations and 23% (15/64) and 6% (4/66)

had events that were mild or moderate in

Table 3. Severe cutaneous AEs were more
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Table 2 Study action taken with study drug as a result of cutaneous AEs
Study action, n (%)

IM IFN beta-1a

Daclizumab HYP

Patients randomized to treatment

922 (100)

919 (100)

Cutaneous AE that led to discontinuation of study drug

7 (0.8)

43 (4.7)

Cutaneous AE that led to study withdrawal

4 (0.4)

15 (1.6)

176 (100)

344 (100)

No action take as a result of cutaneous AE

158 (89.8)

277 (80.5)

Cutaneous AE that led to dose interruption

11 (6.3)

24 (7.0)

7 (4.0)

43 (12.5)

Patients with a cutaneous AE

Cutaneous AE that led to withdrawal of study drug

The categories are mutually exclusive, and an event was counted in only one category starting with the worst category as
follows: drug withdrawn, then dose interrupted, then no action
AE adverse event, HYP high-yield process, IFN interferon, IM intramuscular

frequent in daclizumab HYP-(2%) versus IM IFN

AEs in the IM IFN beta-1a group. Most

beta-1a-treated (\1%) patients (Table 3). The
median (range) onset to first moderate or severe

cutaneous AEs were reported as resolved in the
daclizumab HYP (78%, 525/670) and IM IFN

cutaneous AE was 413 (1–1121) days in the

beta-1a

daclizumab HYP group and 311 (2–1033) days
in the IM IFN beta-1a group. When evaluated by

daclizumab HYP and IM IFN beta-1a groups,
144/190 (76%) and 56/66 (85%) moderate

12-week intervals, the rate of appearance of
moderate or severe cutaneous AEs was steady

cutaneous AEs and 18/23 (78%) and 1/3 (33%)
severe cutaneous AEs were reported as resolved.

(82%,

203/247)

groups.

In

the

groups

Most patients with mild cutaneous AEs

(Fig. 1b); however, the overall incidence of
moderate or severe cutaneous AEs was higher

(daclizumab HYP: 81%, 155/191; IM IFN
beta-1a: 87%, 106/122) or moderate cutaneous

with daclizumab HYP than with IM IFN beta-1a
over the duration of the study (see Figure S1).

AEs (daclizumab HYP: 72%, 95/132; IM IFN
beta-1a: 73%, 37/51) did not require treatment

Based on currently available evidence, there is

with corticosteroids or were treated with topical

no clear association between cutaneous AEs and
efficacy in daclizumab HYP-treated patients

corticosteroids (Fig. 2). In patients with severe
cutaneous AEs, 81% (17/21) of daclizumab

(data on file [Biogen]). Visual examples of
mild, moderate, and severe cutaneous AEs in

HYP-treated patients and 33% (1/3) of IM IFN
beta-1a-treated patients received systemic

daclizumab HYP-treated patients are shown in

corticosteroids (Fig. 2).

over

96 weeks

in

both

treatment

Figure S2.
Serious Cutaneous AEs
Resolution and Management
Serious cutaneous AEs were reported in 14 (2%)
A total of 670 cutaneous AEs were reported in
the daclizumab HYP group and 247 cutaneous

daclizumab HYP-treated patients and one (\1%)
IM IFN beta-1a-treated patient. In the

Adv Ther

Table 3 Cutaneous AEs by severity

Table 3 continued

MedDRA Preferred Term

IM IFN
beta-1a
(n 5 922)

Daclizumab
HYP
(n 5 919)

Any mild cutaneous AEa

122 (13)

191 (21)

Rash

21 (2)

47 (5)

Eczema

9 (\1)

30 (3)

Dry skin

4 (\1)

20 (2)

Erythema

14 (2)

18 (2)

Seborrhoeic dermatitis

2 (\1)

18 (2)

Acne

9 (\1)

17 (2)

Pruritus

14 (2)

17 (2)

51 (6)

132 (14)

5 (\1)

15 (2)

3 (\1)

21 (2)

Dermatitis

0

3 (\1)

Maculopapular rash

0

3 (\1)

daclizumab

Rash

0

2 (\1)

Angioedema

0

1 (\1)

angioedema were reported by the investigators
in three and two patients, respectively; all other

Atopic dermatitis

0

1 (\1)

Decubitus ulcer

0

1 (\1)

DRESS

0

1 (\1)

Dry skin

0

1 (\1)

oral sebaceous cyst considered unrelated to
study treatment in a patient with a history of

Eczema

0

1 (\1)

cigarette smoking who was admitted to the

Erythema

0

1 (\1)

Erythema multiforme

0

1 (\1)

hospital for removal of the cyst (Table 4).
Among serious cutaneous AEs in the

Erythrodermic psoriasis

0

1 (\1)

daclizumab HYP group, investigators classified
ten as severe, two moderate, and two mild in

Exfoliative dermatitis

0

1 (\1)

severity, and three as not related to study drug

Lichenoid keratosis

0

1 (\1)

Pityriasis rubra pilaris

0

1 (\1)

(Table 4). In the daclizumab HYP group, six
patients discontinued treatment due to a

Psoriasis

0

1 (\1)

serious cutaneous AE but remained in the
study, and two patients withdrew from the

Seborrhoeic dermatitis

0

1 (\1)

study due to a serious cutaneous AE but

Toxic skin eruption

0

1 (\1)

continued to be monitored (Table 4). All

Any moderate cutaneous AEa
Rash
Any severe cutaneous AE

MedDRA Preferred Term

IM IFN
beta-1a
(n 5 922)

Daclizumab
HYP
(n 5 919)

Guttate psoriasis

1 (\1)

0

Rosacea

1 (\1)

0

Urticaria

1 (\1)

0

AE adverse event, DRESS drug reaction with eosinophilia
and systemic symptoms, HYP high-yield process, IFN
interferon, IM intramuscular, MedDRA Medical
Dictionary for Regulatory Activities
a
Mild and moderate cutaneous AEs in C2% of patients in
either treatment group. For each Preferred Term, a patient
was only counted once under the greatest severity.
However, within a given severity rating, a patient may
have experienced more than one cutaneous AE reported
under different Preferred Terms but with the same
severity. Cutaneous AEs listed in descending order in the
daclizumab HYP group
HYP

group,

dermatitis

and

serious cutaneous AEs were reported in one
patient each (Table 4). The serious cutaneous AE
in the IM IFN beta-1a group was reported as an

Adv Ther

Fig. 2 Corticosteroid treatment in patients with cutaneous AEs by AE severity and for serious cutaneous AEs. AE adverse
event, HYP high-yield process, IFN interferon, IM intramuscular
serious cutaneous AEs resolved. Patients with
serious cutaneous AEs in the daclizumab HYP

hospitalized for a worsening rash. In the
hospital, the patient was treated with

group were frequently treated with systemic

high-dose corticosteroids and one course of

corticosteroids (Fig. 2).
One case of drug reaction with eosinophilia

plasma exchange consisting of one treatment.
The event resolved. The blinded independent

and systemic symptoms (DRESS) was reported
in a patient who had previously discontinued

central dermatologist considered the event to
more likely represent a grade 2 delayed-type

daclizumab HYP 128 days before the onset of

hypersensitivity cutaneous reaction based on

the serious AE. The patient was treated with
short tapers of betamethasone (maximum dose

the available information. A broad search of the
clinical database was conducted, and no

of 2.5–5.0 mg [equivalent to 21–42 mg of
prednisone]) or betamethasone 0.5 mg (4-mg

additional cases were found that met the
RegiSCAR criteria [10] for DRESS based on

prednisone

medical review of the cases.

equivalent)

before

being

Adv Ther

Table 4 Serious cutaneous AEs
Treatment group
MedDRA Preferred Term
(investigator term)

Severity

No. of
doses
at onset

History of
dermatologic
condition

Action taken as a result
of serious cutaneous
AE

NR

Withdrew from study

Yes (psoriasis rash)

Study drug permanently
discontinued

Related to study druga
Daclizumab HYP
Dermatitis (dermatitis)

Severe

3

Dermatitis (interface dermatitis)

Severe

13

Dermatitis (toxic dermatitis)

Severe

4

NR

Noneb

Angioedema (hypersensitivity
reaction like as Quincke’s
edema)

Mild

16c

NR

Noned

DRESS (toxic dermatitis/DRESS
syndrome)

Severe

4

NR

Noneb

Leukocytoclastic vasculitis (necrotizing
leukoytoclastic vasculitis)

Moderate

17

NR

Study drug permanently
discontinued

Lichenoid keratosis
(generalized lichenoid
reaction)

Severe

17

NR

Study drug permanently
discontinued

Pityriasis rubra pilaris
(pityriasis rubra pilaris)

Severe

9

Yes (allergic rash to
penicillin, latex)

Study drug permanently
discontinued

Pustular psoriasis (pustulosis of
palms and plantas)

Moderate

6

NR

Withdrew from study

Maculopapular rash (diffuse
maculopapular rash)

Severe

25

NR

Study drug permanently
discontinued

Toxic skin eruption (toksikodermiya
unclear origin)

Severe

22

NR

Study drug permanently
discontinued

137

NR

Noned

Not related to study druga
IM IFN beta-1a
Dermal cyst (sebaceous cyst of the
sublingual area)

Moderate

Daclizumab HYP
Angioedema (face angioedema with
urticaria)

Severe

9

NR

Noned

Decubitus ulcer (bed sore)

Severe

4

NR

Nonee
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Table 4 continued
Treatment group
MedDRA Preferred Term
(investigator term)
Psoriasis (psoriasis exacerbation)

Severity

No. of
doses
at onset

History of
dermatologic
condition

Action taken as a result
of serious cutaneous
AE

Mild

19

Yes (psoriasis)

Noned

AE adverse event, DRESS drug reaction with eosinophilia and systemic symptoms, HYP high-yield process, IFN interferon,
IM intramuscular, MedDRA Medical Dictionary for Regulatory Activities, NR none reported
a
Relationship to study drug as assessed by the investigator
b
The patient had previously discontinued treatment due to a non-serious cutaneous AE; however, no study action was
taken as a result of the serious cutaneous AE and the patient continued in the study
c
The number of doses was based on an estimated date of onset because the date of onset was not reported
d
The patient remained on study drug and in the study
e
At the time this serious cutaneous AE was reported, the patient had been withdrawn from the study (consent withdrawn).
No study action was taken as a result of the serious cutaneous AE. The patient had a brain stem relapse before the onset of
this serious cutaneous AE and subsequently died as a result of aspiration pneumonia
Adjudication by Blinded Dermatologist

Stevens–Johnson syndrome or toxic epidermal
necrolysis.

Based on the evaluation of cutaneous AEs in
DECIDE, the central dermatologist concluded
that daclizumab HYP was associated with an

DISCUSSION

increased risk of cutaneous AEs. The central
dermatologist
reviewed
and
provided

In DECIDE, daclizumab HYP was associated

assessments for all cutaneous AEs considered
clinically significant by the investigators. Over

2–3 years of treatment compared with IM IFN
beta-1a in patients with RRMS. Relevant

the

medical history of dermatological conditions
exacerbated this risk to a similar degree in both

course

of

the

study,

the

central

dermatologist reviewed case reports for 42%
(284/670) of all cutaneous AEs in the

with a higher risk of cutaneous AEs over

treatment

groups.

Consistent

with

these

daclizumab HYP group and 28% (70/247) of
all cutaneous AEs in the IM IFN beta-1a group.

observations, the incidence of cutaneous AEs
was higher with daclizumab HYP 150 mg SC

The overall subjective impression of the central

(18%) than placebo (13%) in the 1-year SELECT
study [6]. Cutaneous AEs reported here are

dermatologist was that cutaneous AEs in
DECIDE resembled eczematous or psoriasis-like

distinct from injection site reactions, which

events or were typical of skin conditions
commonly encountered in a dermatology

are localized and temporally linked to the
injection [11].

clinic. In addition, there were a small number

Consistent with these findings, a recent
open-label,
prospective
study
has

of cases that were classified as delayed-type drug
hypersensitivity,
most
of
which
were

demonstrated a high frequency of new-onset

mild-to-moderate in severity. In the opinion of
the blinded central dermatologist, there were

cutaneous events associated with daclizumab
HYP administration in patients with RRMS [12].

no

The majority of cutaneous findings in this study
were
consistent
both
clinically
and

cases

that

represented

life-threatening

events. There were no reported cases of
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histologically with an eczematous dermatitis

cutaneous event guidelines and were made

[12]. In biopsies, cellular infiltrates in the

aware of this type of AE, a higher treatment

epidermis and dermis consisted of abundant T
cells, and immunohistochemistry revealed

rate with corticosteroids may have resulted
from the distribution of these guidelines.

increased expression of CD56, highlighting
either NK cells or CD8? T cells amongst them

The potential link between the underlying
mechanisms of daclizumab HYP and cutaneous

[12]. The authors suggested that cutaneous

AEs is unclear. Skin-resident regulatory T (Treg)

events represent pharmacologic (mechanistic)
immune modulation by daclizumab HYP, rather

cells may counteract inflammatory T cell
responses, and alterations in Treg cell function

than
typical
drug
hypersensitivity-type
reactions [12]. A previous chart review study

in the skin have been observed in psoriasis [16].
CD25 blockade results in both expansion of

identified a case of alopecia following the

CD56bright natural killer cells [17, 18] and

development of a severe exfoliative rash in a
patient treated with intravenous daclizumab

reversible declines in the number of
circulating Treg cells in patients with RRMS

(ZenapaxÒ, Roche Laboratories, Nutley, NJ,
USA) [13]. Both the rash and alopecia resolved

[19, 20]. Treg cells remaining in circulation
during CD25 blockade appeared to preserve

following discontinuation of daclizumab and

the Treg phenotype [19], although reductions

corticosteroid treatment [13]. In the DECIDE
study, alopecia was reported in 16 (2%) patients

in suppressive capacity have been observed [20].
As such, the relationship between reductions in

in the daclizumab HYP group (see Table 1). All
of these cases of alopecia were mild or moderate

Treg cells and cutaneous AEs during CD25
blockade is currently inconclusive [19, 20].

in severity; no cases of severe alopecia were
reported (see Table 3).

Additional work is required to determine
whether compartmental differences exist in

A strength of DECIDE was the inclusion of a

the

maintenance

of

organ-specific

blinded central dermatologist, which allowed
for accurate monitoring and assessment of

self-tolerance by Treg cells [20].
Early recognition and treatment

cutaneous AEs. One limitation of this study
was that very few biopsies were performed on

inflammatory skin conditions offers the best
chance for reversing or limiting flares of the

cutaneous lesions. Results from biopsies may

disease

have provided valuable information to better
understand the nature of the cutaneous AEs. In

guidelines
including

addition, photographs of cutaneous AEs were
limited in number and some were of insufficient

corticosteroids, for psoriasis and eczema
[23, 24]. Moisturizers maintain skin hydration

quality to be useful. Interpretation of the rates

and

of resolution of cutaneous AEs in both
treatment groups may be limited by the

corticosteroids are recommended to decrease
inflammation, and numerous formulations are

background rate of chronic dermatologic
conditions known to occur in both the general

available that range in relative potency (see
Table S2) [23, 24]. Higher-potency topical

[21,

can

22].

Dermatologic

recommend
moisturizers

reduce

topical
and

itching

[23].

of

treatment
agents,
topical

Topical

population and in patients with MS [14, 15] and

corticosteroids are generally recommended as

by incomplete data in patients who withdrew
from the study with an ongoing non-serious AE.

the initial therapy for acute flares on most body
parts in adults, and lower-potency agents for

Because

maintenance

investigators

were

provided

with

therapy

[23,

24].

Topical
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treatments, including corticosteroids, are also

AEs, more than one-third (133/344 [39%]) had

recommended for use with systemic treatments

investigator-reported AEs coded to the MedDRA

in more extensive eczema or psoriasis [23, 24].
Systemic corticosteroids are only recommended

High Level Term dermatitis and eczema (see
Table 1). Although eczematous events are a

for acute severe exacerbations of eczema [25],
and are generally contraindicated in psoriasis

nuisance, they typically tend to be reversible
and do not result in skin damage or organ

[26]. The overall pattern of corticosteroid

failure even if present for extended periods

treatment for cutaneous AEs in DECIDE was
generally consistent with these treatment

[26, 30]. Chronic rashes are likely driven by the
interplay between genetic predisposition,

guidelines, wherein topical corticosteroids
were more frequently used for mild and

immune response, and environmental factors
(e.g., tendency for re-emergence of eczema in

moderate

cutaneous

AEs

and

systemic

humans) [22]. Importantly, daclizumab HYP did

corticosteroids for severe or serious events.

not lead to cutaneous AEs that resulted in loss of
skin structure or function. Most cutaneous AEs

Dermatologic Perspectives of Daclizumab
HYP-Related Cutaneous AEs

during daclizumab HYP treatment were not
allergic reactions. However, a small number of
drug-type

For the range of cutaneous AEs observed in both

hypersensitivity

reactions

were

treatment groups in DECIDE, one must have an

identified; these reactions need to be
distinguished from inflammatory diseases, as it

understanding of the overall frequency of skin
diseases across world populations and the

may be necessary to discontinue drugs that
drive drug-type hypersensitivity reactions.

function of skin as an immunologic organ in
both health and disease. Surveys have shown

Overall, early diagnosis and treatment of
cutaneous
AEs
following
established

that eight of the most common medical
problems in humans are skin conditions [27],

dermatologic management guidelines offer the

a frequent

best opportunity for resolution.
We speculate that many of the inflammatory

investigator-reported diagnosis in DECIDE.
Atopic eczema is also a common skin

skin conditions noted in DECIDE relate
mechanistically to the function of skin as an

condition in up to 30% of children, where the
majority outgrow eczema by early adulthood

immune organ and to mechanistic effects on

including

eczema,

which

was

but there is also an increasing frequency of

Treg cells or other regulatory immune
mechanisms. Skin contains resident dendritic

adult-onset
populations

atopic eczema across world
[21, 28, 29]. Hence, one

antigen-presenting cells and skin-homing
resident memory T cells; therefore, immune

perspective is that a large range of common
skin conditions are also seen in the DECIDE

reactions confined only to the skin are possible

study population. Within the spectrum of

[16, 31]. The range of commonly encountered
skin diseases, such as atopic eczema and

cutaneous AEs in DECIDE, there was a large
representation of eczema and eczema-spectrum

psoriasis, represent excessive activation of T
cells in the skin, and skin inflammation is

conditions (i.e., allergic dermatitis, eczema,
nummular dermatitis, and hand dermatitis)

produced by effects of T cell-derived cytokines

[29], which may be classified as inflammatory

on resident skin cells, in part enabled by the
reduced function of Treg cells [32]. Targeted

skin diseases. Among patients with cutaneous

removal of cutaneous Treg cells in model
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production of cytokines that typify atopic

in the development of this paper; Alison
Gagnon, Ph.D., from Excel Scientific Solutions

eczema and related diseases [33]. Hence, the
decrease in Treg cells noted in circulating T cells

wrote the first draft of the manuscript based on
input from authors, and Kristen DeYoung from

during daclizumab HYP treatment [19, 20] may
well extend to diminished function of these

Excel Scientific Solutions copyedited and styled
the manuscript per journal requirements.

cells with the cutaneous compartment, leading

Biogen

to unmasking or activation of resident T cell
populations
that
mediate
psoriasis
or

reviewed and provided feedback on the paper
to the authors. The authors had full editorial

eczema-spectrum conditions.

control of the paper, and provided their final
approval of all content. Some of these data have

CONCLUSION

been presented previously as an abstract and

systems produces skin inflammation and excess

In summary, cutaneous AEs in daclizumab
HYP-treated

patients

were

predominantly

mild-to-moderate in severity, treated with
topical corticosteroids or did not require
treatment with a corticosteroid, and resolved.
More severe or serious cutaneous AEs frequently
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